1) Pre-organoid engineering

Use when: you want to introduce mutations, reporters, or isogenic controls before differentiation.

Why: donor cells, iPSCs, and primary-like cells are often difficult to transfect, and electroporation can support efficient delivery while preserving viability.

Decision enabled: is this edit or model worth building into a long-term organoid line?

2) Organoid editing after dissociation

Use when: you want to label organoids, test reporters, perturb pathways, or prototype editor constructs.

Why: dissociate → electroporate → reaggregate is often faster than building and validating virus.

Decision enabled: does the construct work and produce the intended phenotype in this organoid context?

3) Immune co-culture engineering

Use when: T cells, NK cells, or macrophages need to be engineered for co-culture assays.

Why: non-viral delivery can accelerate perturb → co-culture → readout loops.

Decision enabled: does immune engineering change killing, inflammation, or disease phenotype?

4) In vivo or ex vivo tissue electroporation

Use when: the workflow bridges organoids into animal or tissue models.

Why: it provides continuity between in vitro and tissue-level perturbation without changing platforms.

Decision enabled: does the biology translate from organoid context into tissue context?

5) Rapid CRISPR screening loops

Use when: multiple guides or targets need to be tested before committing to stable lines.

Why: acute RNP or transient expression workflows avoid viral prep time and cost.

Decision enabled: which targets are worth turning into a stable, scalable viral model?

1) Early go / no-go on constructs, variants, and targets

• Decision: Is this perturbation worth building as a stable model?
• Why NEPA21: same-day delivery; results in days; no vector build, titer, or selection to start.
• Applies to: CRC, PDAC, Brain, Lung, Kidney—especially large patient-derived organoid panels.

2) Acute CRISPR knockout to test immediate dependencies

• Decision: What happens right after gene loss—before adaptation?
• Why NEPA21: acute RNP knockout is fast, low footprint, and avoids long-term Cas9 expression.
• High value in: CRC / PDAC, Kidney, Lung, and Brain models.

3) Mechanism check: cell-autonomous vs non-autonomous effects

• Decision: Is the phenotype intrinsic to edited cells or driven by neighbours and context?
• Why NEPA21: mosaic delivery can create within-organoid controls.
• High value for: CRC / PDAC fitness questions, Brain signalling and patterning, Lung state changes, Kidney injury susceptibility.

4) Throughput scaling across patient-derived cohorts

• Decision: Is the effect consistent across many patients or genotypes?
• Why NEPA21: lower per-condition cost and no custom virus per construct makes broad testing more feasible.
• Applies to: CRC/PDAC/Lung/Kidney PDO biobanks; brain tumour organoids
  
  
  

5) Large or multi-component payload feasibility

• Decision: Can this big construct or multi-plasmid system work at all?
• Why NEPA21: supports large plasmids and easy co-delivery of reporter + effector + barcode.
• Applies to: complex reporter/perturbation systems across all tissues.
  
  

6) Timing-sensitive interventions

• Decision: Does timing matter, such as early vs late organoid stage?
• Why NEPA21: target specific stages without waiting for viral expression or selection.
• Applies strongly to: Brain developmental studies, plus Lung and Kidney differentiation windows.
  
  

7) Fast perturb → treat pharmacology loops

• Decision: Does gene or pathway X modify response to therapy or stress within a week?
• Why NEPA21: acute perturbation + drug exposure is fast and clean; mosaicism can reveal relative fitness.
• Applies to: CRC, PDAC, Brain, Lung, and Kidney workflows.
  
  
  

8) Minimal-genomic-footprint needs

• Decision: Do you need to avoid integration and persistent transgene expression?
• Why NEPA21: RNP and transient expression minimize genomic footprint and integration concerns.
• Applies to: translational/preclinical workflows and multi-PDO perturbation studies
  
  

When labs choose it

• early validation of constructs, targets, or variants
• acute CRISPR editing with RNPs
• fragile primary or stem-cell–derived models where viability matters
• large or multi-part cargo that is difficult to package virally
• experiments where mosaicism is useful rather than a limitation
  
  
  
  

Typical strengths

• rapid setup and fast results
• non-viral workflow with lower routine biosafety overhead
• compatible with plasmids, RNA, and RNPs
• tuneable pulse settings for different organoid types
• useful as a decision tool before investing in stable viral workflows
  
  
  

Typical trade-offs

• expression is usually transient unless paired with downstream selection or line derivation
• delivery may be heterogeneous
• broad uniform perturbation is harder than with optimized viral systems
• protocols often require sample-specific optimization

Typical workflow

1. prepare donor cells, dissociated organoid cells, or the target organoid format
2. mix DNA, RNA, or RNP payload
3. apply a NEPA21 poring + transfer pulse program optimized for the sample
4. recover and culture
5. analyse early phenotype, expression, editing, or feasibility
6. decide whether to proceed to stable viral standardization
   
   
   

The strategic handoff

Switch to AAV, lenti, or retro when the next decision requires uniform perturbation, stable long-term expression, inducible systems, lineage tracing, clonal reproducibility, or larger-program standardization.

For many labs:
NEPA21 to decide    →     viral to standardize.

That avoids over-investing in viral builds for constructs, targets, or payloads that have not yet earned a longer-term program